New lupus drug candidate enters Mid-Stage testing

NCT ID NCT07299422

Recruiting now Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 clinical trial is testing an investigational drug called SHR-2173 in about 248 adults with active systemic lupus erythematosus (SLE). Participants will receive either the drug or a placebo for 24 weeks, with follow-up. The main goal is to see if SHR-2173 can reduce lupus disease activity better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-2173 injection
What this could lead to: If successful, this could lead to a new treatment option for people with active lupus, helping control disease activity and reduce symptoms.
What could go wrong: This is an early Phase 2 trial with a moderate number of participants. The drug may not prove more effective than placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100005, China
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.